Background--Recent studies indicate that a1-adrenergic receptors (a1-ARs) are cardioprotective by preventing cardiac myocyte death and augmenting contractility in heart failure. Although G-protein-coupled receptors are assumed to localize to and signal at the plasma membrane, we previously demonstrated that endogenous a1-ARs localize to the nuclei in adult cardiac myocytes. However, the functional consequence of this nuclear localization remains unclear. Here, we attempted to reconcile nuclear localization of a1-ARs with their physiologic function by examining a1-AR-induced contractility in adult cardiac myocytes.
I
n heart failure, elevated catecholamine levels leading to increased activation of adrenergic receptors (ARs) are believed to exacerbate pathologic ventricular remodeling. However, recent clinical and animal studies indicate that a1-ARs have an important and previously unpredicted cardioprotective role in heart failure, despite accounting for only 11% of total ARs in the heart. 1, 2 In clinical trials, a1-AR antagonists doubled the risk of heart failure in hypertensive patients 3 and tended to reduce survival in heart failure patients. 4 These findings are consistent with a1-AR cardioprotection and are further supported by analogous studies in mice. In mice lacking cardiac a1-ARs (a1A-and a1B-AR double knockout mice; a1ABKO), we found that pathologic stress from pressure overload reduced survival and induced heart failure in surviving mice characterized by cardiac myocyte cell death, contractile dysfunction, fibrosis, and a failure of cardiacspecific gene transcription. 5, 6 Furthermore, we identified an a1A subtype/extracellular signal-regulated kinase (ERK) survival-signaling pathway in adult cardiac myocytes, the absence of which might explain the maladaptive response to pathologic stress in a1ABKO mice. 7, 8 In addition, others have shown that transgenic overexpression of the a1A subtype prevented pathologic remodeling in response to pressure overload and ischemic injury. 9, 10 These studies contradict the widely held idea that all AR signaling in heart failure is detrimental, and suggest that activation of cardioprotective a1-AR signaling could be a novel therapy for heart failure. 1, 2 There are 3 a1-AR subtypes (a1A, a1B, and a1D), and whereas all 3 subtype mRNAs are expressed in the heart, only nuclear a1-AR signaling was facilitated by rapid catecholamine uptake mediated by the membrane transporter, organic cation transporter 3. 15 However, whereas our data indicated that at least 80%, and possibly all, a1-ARs localized to the nucleus in adult cardiac myocytes, 15 previous reports suggested that only 5% of ET-Rs localized to the nucleus (AT-R levels are too low to make such measurements). 13, 16 Based on this differential localization, we previously suggested that Gq-coupled receptor signaling might be compartmentalized, with nuclear Gq-coupled receptors, such as a1-ARs, being cardioprotective. 16 However, mechanisms by which nuclear GPCRs signal and regulate physiologic function remain difficult to define. 17 ET-Rinduced calcium transients and AT-R-and b-AR-induced gene transcription have been observed in nuclei isolated from adult cardiac myocytes. 13, 14, 18 Yet, ascribing a physiological function to these nuclear receptors is difficult because the majority of these receptors localize to the plasma membrane. Conversely, a1-ARs localize primarily to the nucleus, 15, 16 which would suggest that a1-AR signaling must arise from the nucleus. Therefore, to reconcile nuclear localization of a1-ARs with a1-AR physiologic function, we examined a1-AR-mediated contractile function in adult cardiac myocytes. Our results define a novel "inside-out" contractile signaling pathway in adult cardiac myocytes, where nuclear a1-ARs activate protein kinase Cd (PKCd), leading to phosphorylation of cardiac troponin I (cTnI) at the sarcomere. Finally, our data help resolve the discrepancy between nuclear localization of a1-ARs and a1-AR-mediated physiological function.
Methods Experimental Animals
Generation of a1ABKO double knockout mice was previously described. 5 Congenic C57BL/6J mice (12th to 15th generation, between 10 and 15 weeks of age) were used in all experiments. The use of all animals in this study conformed to the Public Health Service Guide for Care and Use of Laboratory Animals and was approved by The University of Minnesota and Sanford Research/University of South Dakota Institutional Animal Care and Use Committees.
Culture of Adult Mouse Cardiac Myocytes
Procedures for the isolation and culture of adult mouse cardiac myocytes were previously described. 19 
Chemicals
All reagents were prepared with chemicals purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise noted.
Adenoviruses
The a1A-GFP (green fluorescent protein) and a1A-NLSmut constructs were described previously. 8, 16 PKCd constructs were made using a human cDNA encoding PKCd (GenBank L07860), amplified by PCR with primers (IDT) containing Xho I (5 0 ) and Kpn I (3 0 ) restriction sites, and subcloned into the multicloning site of pDsRed monomer-C1 (Clontech Laboratories, Mountain View, CA) in frame. Dominant negative PKCd (PKCd-DN) was made by a K?A mutation at position 378 by site-directed mutagenesis using the QuikChange kit (Stratagene, La Jolla, CA). 20 The PKCd nuclear localization mutant (PKCd-NLSmut) was made with a DNA minigene (IDT) containing the PKCd NLS flanked by unique XcmI and AscI sites, but with the arginines (R) or lysines (K) replaced with alanine (A) at positions 613, 614, 615, 621, 623, 625, and 628 corresponding to the human sequence. 20 All DsRed-PKCd constructs were subcloned into the AdEasy system (Stratagene) for adenovirus production. For all experiments, cardiac myocytes were infected at a multiplicity of infection of 1000 for the a1A-AR constructs, resulting in 2.5-fold overexpression for the a1A-AR, 8 and 5-fold overexpression for the PKCd constructs.
Measurement of ERK Activation in HeLa Cells
HeLa cells were plated at a density of 70 000 cells per 35-mm plate overnight. The next day, cells were infected with an a1-NLS mutant at a multiplicity of infection of 1000. Forty hours postinfection, cells were treated with 20 lmol/L of phenylephrine (PE) for 20 minutes at 37°C (5% CO 2 ). For each treatment, 20 lg of total cell protein were resolved by SDS-PAGE, transferred to PVDF, and probed with either antibodies to phospho-ERK (pERK) or total ERK (tERK) (1:1000; Cell Signaling Technology, Danvers, MA). and fura2 ratio (340/380 nm), respectively, were recorded using the Fluorescence and Contractility System (IonOptix LLC, Milton, MA). In each experiment, data were collected from 4 to 8 myocytes per heart or treatment.
Measurement of Cardiac Myocyte Contractility

Measurement of the Phosphorylation of cTnI and Phospholamban
To measure the phosphorylation state of cTnI and phospholamban (PLB), isolated cardiac myocytes were plated in 35-mm dishes, infected with adenovirus, and cultured for 40 hours. After 40 hours, myocytes were pretreated with timolol (2 lmol/L) and, in some cases, also with lepB (18.5 nmol/L) for 30 minutes followed by PE (20 lmol/L) for 5 minutes at 37°C. Whole-cell lysates were prepared as described previously. 16 
Biochemical Fractionation of Cardiac Myocytes
Procedures for the biochemical fractionation of freshly isolated cardiac myocytes were described elsewhere. 15 The purity of each fraction was verified by Western blot using primary antibodies against Na + /Ca 2+ exchanger (NCX; plasma membrane, 1:1000 dilution; Millipore), glyceraldehyde 3-phosphate dehydrogenase (GAPDH; cytosol, 1:100 000 dilution; Fitzgerald Industries International, Inc., Acton, MA), and lamin-associated protein 2 (LAP2; inner nuclear membrane marker, 1:1000 dilution; BD Biosciences, San Jose, CA).
Measurement of Nuclear PKC Expression and Signaling
To measure subcellular distribution of PKC isozymes, cardiac myocyte fractions were resolved as described above and then examined by Western blot. Western blots were probed with primary antibodies to PKC a, d, and e (Santa Cruz Biotechnology), and PKC distribution was quantified using ImageJ software (NIH). To measure nuclear PKC isozymes by immunocytochemistry, isolated myocyte nuclei were incubated with antibodies to PKC a, d, and e (1:1000; Santa Cruz Biotechnology) overnight at 4°C. Nuclei were washed with PBS and then incubated with a Texas Red-conjugated secondary antibody (Invitrogen) for 1 hour at 4°C. Nuclei were again washed with PBS and then mounted onto glass slides with Fluoromount G (Electron Microscopy Sciences) and counterstained with the DNA marker, DAPI. Fluorescent images were captured by confocal microscopy as described above. To measure nuclear PKC activation and activity, 100 lg of isolated nuclei were treated with PE (20 lmol/L) for 20 minutes at 37°C and then nuclear proteins were resolved by SDS-PAGE. To assess nuclear PKCd activation by Western blot, an antibody against phospho-PKCd at Thr505 was used (1:1000; Cell Signaling). To determine nuclear PKC activity by Western blot, an antibody against phospho-myristoylated alanine-rich C kinase substrate (pMARCKS) was used (1:1000; Cell Signaling). LAP2 levels were measured as described above and used as loading controls and proteins were quantified as above.
Statistical Analysis
All values are expressed as meanAESEM. All contractility and Western blot data were analyzed for normality using both D'Agostino-Pearson's and Shapiro-Wilk's normality tests. In Figures 1A through 1C, 2B through 2D, 3A through 3C, and 6C, untransformed data were not normally distributed, but log transformation resulted in P>0.05 in these normality tests. Data in Figure 6B were normally distributed (P>0.05), so no further transformation was performed. Subsequently, data were analyzed by 2-way ANOVA with repeated measures followed by Bonferroni's post-test to compare groups, except for PKC activation and activity, where Student's t test was performed, and P<0.05 was considered significant. The specifics of each statistical analysis and P values are indicated in each figure legend. The number of measurements (n) is stated in each figure legend. In this case, the unit of measurement for the statistical analysis was the cardiac myocytes. However, both the number of different hearts used and the total number of myocytes are included to conform with convention. The exception was for nuclear fractionation studies, where 2 hearts were used in each preparation. A potential limitation of this study was the relatively small numbers used, resulting in a low power in the statistical analysis. Prism 6 software (GraphPad Software, Inc., La Jolla, CA) was used to conduct all statistical analyses.
Results
a1-ARs Regulate Contractility Through Phosphorylation of cTnI at Thr144 in Adult Cardiac Myocytes
Here, we investigated the mechanisms regulating a1-ARmediated contractility by measuring sarcomeric shortening and calcium transients in unloaded adult mouse cardiac myocytes. 21 We found that the a1-agonist, PE (10 lmol/L), in the presence of the b-blocker, timolol (TML; 2 lmol/L), produced the standard triphasic response, although the third phase remained negative, as others have observed in isolated adult mouse cardiac myocytes. 22, 23 After 5 minutes, PE significantly decreased sarcomere shortening in WT adult mouse cardiac myocytes ( Figure 1A , single-twitch contraction shown at 5 minutes, and percent [%] sarcomere shortening at 5 minutes shown on right). As expected, PE had no effect on sarcomere shortening in a1ABKO adult cardiac myocytes, which lack endogenous a1-ARs ( Figure 1A ). Interestingly, PE had no effect on calcium transients in WT or a1ABKO cardiac myocytes ( Figure 1B , single calcium transient shown at 5 minutes and DCa 2+ at 5 minutes shown on right).
Older studies proposed that a1-ARs induce a positive inotropic response by increasing myofilament calcium sensitivity through phosphorylation of myosin light chain 2 24 or phosphorylation of cTnI at the protein kinase A (PKA) sites, serine 23, 24 (Ser23, 24) . 23 Here, we examined a1-AR-mediated phosphorylation of cTnI at multiple sites, including threonine 144 (Thr144), a PKC site identified as decreasing myofilament calcium sensitivity, and the PKA sites, Ser23,24, which are known to increase the rate of relaxation. 25 In WT adult cardiac myocytes, PE increased the phosphorylation of cTnI at Thr144, but had no effect on the phosphorylation of cTnI at Ser23,24 ( Figure 1C ). As expected, PE had no effect on cTnI phosphorylation in a1ABKO adult cardiac myocytes ( Figure 1C ). To control for potential off-target PE activation of b-ARs, we measured phosphorylation of PLB at the PKA site Ser16 and the calcium/calmodulin-dependent kinase site, Thr17. 25 In WT and a1ABKO adult cardiac myocytes, PE had no effect on the phosphorylation of PLB at Thr17 ( Figure 1D , no signal detected at Ser16), consistent with the lack of an effect on the calcium transient ( Figure 1A and 1B). Together, our data suggest that a1-ARs induce inotropic responses through phosphorylation of cTnI at Thr144 and hence a decrease in myofilament calcium sensitivity.
Nuclear Localization of a1-ARs Is Required for a1-AR-Mediated Contractility in Adult Cardiac Myocytes
To test whether a1-AR contractile signaling pathways originate in the nucleus in adult cardiac myocytes, we employed multiple approaches. First, we recently identified NLS in the cytoplasmic tail of both the a1A-and a1B-AR subtypes and demonstrated that mutation of these NLS resulted in mislocalization of each receptor away from the nucleus, although, interestingly, neither receptor relocated to the plasma membrane. 16 Furthermore, neither NLS overlapped with residues important for ligand binding or G-protein binding/activation. Functionally, neither the a1A-nor a1B-NLS mutants (a1-NLSmut) mediated PE-induced phosphory-lation of ERK in adult cardiac myocytes, suggesting that nuclear localization is required for a1-signaling. 16 Importantly, both the a1A-and a1B-NLSmuts mediated PE-induced phosphorylation of ERK in HeLa cells, which do not express endogenous a1-ARs and where exogenously expressed a1-ARs do not localize to the nucleus (despite the NLS in each subtype), indicating that the NLS mutations did not simply inactivate the receptors (Figure 2A ). Here, we tested whether nuclear localization was required for a1-AR signaling using the a1-NLSmuts to reconstitute signaling in a1ABKO adult cardiac myocytes. Reconstitution of the WT a1A subtype, but not the a1B subtype, in a1ABKO adult cardiac myocytes restored the PE-induced reduction of sarcomeric shortening and had no effect on the calcium transients, similar to WT adult cardiac myocytes (a1A-WT shown in Figure 2B and 2C; a1B-WT shown in Figure 3 ). This finding is consistent with previous studies indicating that the a1A subtype regulates contractility. 26, 27 In addition, reconstitution of the WT a1A subtype in a1ABKO adult cardiac myocytes restored the phosphorylation of cTnI at Thr144 ( Figure 2D ). More important, reconstitution with the a1A-NLSmut in a1ABKO adult cardiac myocytes failed to restore PE-mediated sarcomeric shortening or phosphorylation of cTnI at Thr144 ( Figure 2B through 2D) . 2+ transients were measured in a1ABKO cardiac myocytes expressing WT a1A-AR (a1A-WT) or the a1A-NLS mutant (a1A-NLSmut) before and 5 minutes after PE treatment (10 lmol/L of PE, 2 lmol/L of timolol in all conditions). Single-twitch contractions or calcium transients are shown at 5 minutes after the addition of PE. Averaged data for percent (%) sarcomere shortening and fold change in calcium (DCa 2+ ) at 5 minutes after PE are presented as meanAESEM from 21 a1ABKO cardiac myocytes expressing the a1A-WT or the a1A-NLSmut from 7 different cultures for each. D, cTnI phosphorylation at Thr144 measured by Western blot from a1ABKO cardiac myocytes expressing a1A-WT or a1A-NLSmut treated with PE (20 lmol/L, 15 minutes). Quantitation of cTnI phosphorylation at Thr144 is presented as meanAESEM from 6 different cultures. All data were analyzed by 2-way ANOVA with repeated measures and Bonferroni's post-test. Percent sarcomere shortening, P=0.0066; DCa 2+ , P=NS; cTnI phosphorylation at Thr144, P=0.0032. Significant comparisons identified by Bonferroni's post-test are indicated as P<0.05. ANOVA indicates analysis of variance; cTnI, cardiac troponin I; ERK, extracellular signal-regulated kinase; NLS, nuclear localization sequences; WT, wild type; a1ABKO, a1A-and a1B-AR double knockout mice; a1-ARs, a1-adrenergic receptors.
Blockade of Nuclear Export Inhibits a1-ARMediated Contractility in Adult Cardiac Myocytes
As an alternative approach to demonstrate that a1-AR signaling originates at the nucleus in adult cardiac myocytes, we employed the nuclear export inhibitor, lepB, which blocks transport through the nuclear pore complex. We previously found that lepB inhibits a1-AR-mediated activation of ERK in adult cardiac myocytes, 16 and others have used lepB to block histone deacetylase export from the nucleus in cardiac myocytes. 28 In the presence of vehicle, PE reduced sarcomeric shortening ( Figure 4A and 4B, single-twitch contraction shown at 5 minutes) and increased the phosphorylation of cTnI at Thr144 ( Figure 4C ) in WT adult cardiac myocytes. In contrast, pretreatment of WT adult cardiac myocytes with lepB tended to reduce the effect of PE on sarcomeric shortening ( Figure 4A ), but significantly reduced PE-induced cTnI phosphorylation ( Figure 4C ). The ability of lepB to inhibit a1-mediated phosphorylation of cTnI agrees with our results with the a1A-NLSmut (Figure 2 ), indicating that a1-inotropic signaling originates in the nucleus.
The a1A Subtype Is Localized in the Inner Nuclear Membrane in Adult Cardiac Myocytes
Our current ( Figure 2 ) and previous data 15, 16 demonstrate that signaling occurs at the nucleus, and our results with lepB further suggest that a1-AR signaling originates inside the nucleus (Figure 4 ), implying localization of a1-ARs to the inner nuclear membrane. To determine a1A-AR localization and orientation in the nuclear bilayer, we used differential permeabilization 29 and immunocytochemistry in a1ABKO
cardiac myocytes expressing the a1A-AR tagged with GFP at the carboxyl tail. This alternative approach was necessitated by the lack of validated, subtype-specific a1-ARs antibodies, 30 preventing conventional electron microscopy approaches. We previously demonstrated that the a1A-GFP reproduces the nuclear localization of endogenous a1-ARs in adult cardiac myocytes. 8, 15 Here, a1ABKO cardiac myocytes expressing the a1A-GFP from the same culture were treated with either Triton X-100, which completely permeabilizes all membranes, or with low-percentage digitonin (0.01%), which permeabilizes only the plasma membrane. As controls for permeabilization, we used antibodies to cTnI, which should stain cTnI in both Triton X-100 and digitonin-treated cardiac myocytes in the cytoplasm, and antibodies to lamin A/C, an inner nuclear membrane protein, 31 which should stain lamin A/C in the nucleus only in Triton X-100-treated cardiac myocytes. To confirm a1A-subtype localization independently, antibodies to GFP were used (in addition to GFP fluorescence). In Triton X-100-treated cardiac myocytes, both lamin A/C ( Figure 5A ) and cTnI ( Figure 5B ) were detected, validating the Triton X-100 permeabilization technique. Furthermore, the a1A-GFP was detected by fluorescence and independently with a GFP antibody, as expected ( Figure 5A and 5B). Conversely, in digitonin-treated cardiac myocytes, cTnI (Figure 5D ), but not lamin A/C ( Figure 5C ), staining was detected, which indicated that antibodies were not reaching Figure 5 . The a1A-subtype is localized in the inner nuclear membrane in adult cardiac myocytes. a1ABKO adult cardiac myocytes expressing a1A-GFP were subjected to differential permeabilization with Triton X-100 (permeabilized plasma and nuclear membranes, left) or with digitonin (permeabilize plasma membrane only, right) and then stained with an anti-GFP antibody, detected by a Cy3-labeled secondary antibody, shown in red (A through D). Fluorescence from the a1A-GFP is shown in green. As controls for the differential permeabilization, cardiac myocytes were also counterstained with the inner nuclear membrane protein, lamin A/C (A and C) or cTnI (B and D) and detected by Cy5-labeled secondary antibody, shown in white. Scale bar=20 lm. Results are representative from 3 separate cultures. cTnI indicates cardiac troponin I; DAPI, 4',6-diamidino-2-phenylindole; GFP, green fluorescent protein; a1ABKO, a1A-and a1B-AR double knockout mice.
the inside of the nucleus. Importantly, whereas a1A-GFP fluorescence was detected, the GFP antibody failed to detect the a1A-GFP ( Figure 5C and 5D ). The failure of the GFP antibody to detect the a1A-GFP in digitonin-treated myocytes indicated that the GFP tag, as with lamin A/C, was not accessible to the antibody. Based on the failure of the GFP antibody in this situation, we would suggest that a1A subtype, as with lamin A/C, is localized to the inner nuclear membrane (not necessarily colocalized, but in the same compartment), with the C-terminus facing the nucleoplasm.
a1-ARs Activate PKC in Nuclei Isolated From Adult Cardiac Myocytes
Consistent with the idea that a1-ARs signal at the nucleus, we previously demonstrated that the a1A and a1B subtypes, Gaq and PLCb1, colocalize only at the nucleus in adult cardiac myocytes. 15 Signaling through a1-ARs also involves activation of PKC. Therefore, we screened for the expression of PKCa, d, and e, the primary PKC isoforms induced by a1-AR signaling, 32 in nuclei isolated from WT adult mouse cardiac myocytes. Immunocytochemistry with PKC isoform-specific antibodies indicated that all 3 PKC isoforms were detected in nuclei isolated from WT cardiac myocytes ( Figure 6A ). Next, we determined the subcellular distribution of PKCs a, d, and e by isolating membrane, cytosolic, and nuclear fractions from WT adult cardiac myocytes. PKCa and d were detected in the nuclear fraction, and among the nuclear PKCs, PKCd expression was proportionally the highest ( Figure 6B ). Membrane, cytosolic, and nuclear fractions were validated by Western blots for NCX, GAPDH, and LAP2, respectively ( Figure 6B ). Based on our identification of a1-AR-signaling molecules in the nucleus, we subsequently measured a1-AR signaling directly in nuclei isolated from WT adult cardiac myocytes. In isolated nuclei, PE significantly increased the phosphorylation of PKCd at Thr505, an autophosphorylation site required for activation, and the phosphorylation of the known PKC substrate, MARCKS ( Figure 6C ). In summary, our results clearly demonstrate that stimulation of nuclear a1-ARs activates PKC, specifically PKCd, and shows that cardiac myocyte nuclei contain machinery sufficient to initiate a1-AR signaling.
Expression of a PKCd Nuclear Localization Mutant Blunts a1A-Receptor Signaling in Adult Cardiac Myocytes
To this point, our results suggest that a1-AR signaling originates in the nucleus and is transduced from the nucleus to the sarcomere to induce phosphorylation of cTnI and thereby regulate contractility (Figures 1 through 5) . Next, we examined PKCd as a potential mediator of a1-AR-induced contractility. DeVries et al. have previously characterized an NLS in PKCd. 20 Because we detected a nuclear population of PKCd that was activated by a1-ARs in WT adult cardiac myocytes ( Figure 5B and 5C), we tested whether nuclear localization of PKCd would affect cardiac myocyte contractility. First, we compared localization of WT PKCd (PKCd-WT) to a PKCd NLS mutant (PKCd-NLSmut) in WT adult cardiac myocytes. As shown in Figure 7A , PKCd-WT was found throughout the cell, notably in the nucleus and Z-disks. In contrast, disruption of the NLS in PKCd prevented its nuclear localization. Next, we found that expression of the PKCdNLSmut tended to reduce the effect of PE on sarcomeric shortening ( Figure 7B ), but significantly reduced PE-induced cTnI phosphorylation ( Figure 7C ), similar to results obtained upon treatment with the nuclear export inhibitor, lepB ( Figure 4) . Together, our results further show that nuclear localization of a1-ARs and PKCd can regulate physiologic responses in adult cardiac myocytes.
Discussion
Here, we sought to establish a physiologic function for nuclear a1-AR signaling in adult cardiac myocytes. Based on our current findings and previous work, 8, 15, 16 we propose a completely novel model for inside-out a1-AR signaling in adult cardiac myocytes (Figure 8 ), where a1-ARs, localized to the inner nuclear membrane, induce signals in the nuclei that are transported to cytosolic (sarcomere) or membrane targets to regulate contractile function and survival signaling.
Our proposed model for nuclear a1-AR signaling and assertion that nuclear a1-AR signaling is physiologically relevant are supported by the following observations. First, we found that the a1A subtype regulated contractility in adult cardiac myocytes, as reported by others, 26 ,27 but we also identified a novel a1-AR sarcomeric target: phosphorylation of cTnI at Thr144 (Figure 1 ). Second, by using an a1A-NLSmut and the nuclear export inhibitor, lepB, we demonstrated that nuclear localization was required for a1-AR signaling (Figure 2) and that a1-AR signaling must have originated in the nucleus (Figure 4) . Third, through differential permeabilization and immunocytochemistry, we found that a1-ARs localized to the inner nuclear membrane with the C-terminus of the receptor facing the nucleoplasm ( Figure 5 ). Fourth, we identified PKCa, d, and e in nuclei isolated from adult cardiac myocytes. Along with our previous demonstration that a1-ARs, Gaq, and phospholipase Cb1 colocalize only at the nuclei in adult cardiac myocytes, 15 this suggests that signaling could occur in the nucleus. In fact, we found that in nuclei isolated from adult cardiac myocytes, a1-ARs induced PKC activation ( Figure 6 ). More important, these findings are consistent with our results showing that nuclear localization was required for a1-AR signaling and that a1-AR signaling originated in the nucleus. Finally, we demonstrated that a1-induced phosphorylation of cTnI at Thr144 was blunted by expression of a PKCd nuclear localization mutant (Figure 7) , further suggesting the signal arose in the nucleus. Our identification of a1-ARs localized to the inner nuclear membrane is provocative (Figure 5 ), because GPCRs are conventionally thought to localize to, and signal at, the plasma membrane. In fact, previous reports have suggested that a1-ARs localize to the plasma membrane in cardiac myocytes, so how can our results be reconciled? Radioligand binding assays and antibodies are the most commonly used techniques to detect receptor expression and localization, but A C B Figure 6 . a1-ARs activate PKC in nuclei isolated from adult cardiac myocytes. A, Nuclei were isolated from adult cardiac myocytes and stained with antibodies to the PKCa, d, or e isoforms followed by DAPI counterstain (scale bar=5 lm). B, PKCa, d, or e isoform distribution in membrane (M), cytosolic (C), and nuclear (N) was measured by Western blot analyses. Fraction purity was verified by Western blots for NCX (membrane), GAPDH (cytosolic), and LAP2 (nuclear). Relative distribution of the PKC isozymes is presented as meanAESEM for 3 separate nuclear preparations. C, PKC activation was measured in isolated nuclei treated with PE (20 lmol/L, 2 lmol/L of timolol) by phosphorylation of PKCd at Thr505. PKC activity was measured by phosphorylation of the PKC substrate, MARCKS (pMARCKS). LAP2, a nuclear marker, was used as a loading control. Quantitation of PKCd phosphorylation at Thr505 and MARCKS phosphorylation is presented as meanAESEM from 3 separate nuclear preparations. Data were analyzed by Student's t test, and significant comparisons are indicated as P<0.05. GAPDH indicates glyceraldehyde 3-phosphate dehydrogenase; LAP2, lamin-associated protein 2; NCX, Na + /Ca 2+ exchanger; PE, phenylephrine; PKC, protein kinase C; pMARCKS, phospho-myristoylated alanine-rich C kinase substrate; a1-ARs, a1-adrenergic receptors.
these techniques have limitations. Radioligand binding assays are typically performed on isolated membrane fractions, which typically do not distinguish membrane fractions (nuclear, for instance), 5, 26, 33 and membrane-impermeable ligands might miss intracellular receptors. 34 Immunocytochemical approaches suffer from the lack of verified a1-AR subtype-specific antibodies, 30 raising doubts about previous studies that relied upon antibodies subsequently shown to be nonspecific. 27, 35 Some previous studies employed membrane fractionation with binding assays to suggest that a1-ARs localize to caveolae. 35, 36 However, using this technique, one study found that only 27% of a1-AR binding was localized to the caveolar fraction in neonatal rat ventricular myocytes, suggesting that a majority of the receptor is localized elsewhere.
36
Whether this undefined receptor population was at the nucleus was unclear in this study, as well as how this result might differ from adult cardiac myocytes. In contrast, using radioligand binding assays on fractionated adult cardiac myocytes or a fluorescent ligand to stain cultured adult cardiac myocytes, we previously demonstrated that at least 80% of a1-ARs localize to the nucleus in adult cardiac myocytes. 15 Our results indicated that nuclear localization was required to initiate signaling (Figure 2 , a1A-NLSmut fails to restore function), and that a1A-subtype signaling arose in the nuclei ( Figure 4C , lepB blocks a1-cTnI phosphorylation). However, a1-mediated contractile function was not entirely inhibited by lepB, suggesting that either not all a1 signaling arises in the nuclei or that not all intranuclear a1 signaling is exported by the nuclear pore complex. Our previous findings that a1 signaling does not originate at the plasma membrane, 15 along with our results with the a1A-NLSmut, are consistent with nuclear a1 signaling. In further support of our hypothesis that signals regulating a1-mediated contractile function arise within the nucleus, previous studies indicated that the a1 agonist, PE, induced an increase in the frequency of inositol 1,4,5-trisphosphate-mediated nuclear calcium transients and can trigger calcium-induced calcium release in the cytosol in cardiac myocytes. 37 Though we propose one mechanism whereby nuclear a1-ARs regulate contractile function, namely, through activation of PKCd and phosphorylation of cTnI, other Figure 8 . Model of nuclear a1-AR signaling in adult cardiac myocytes. The figure depicts a1-ARs localized to the inner nuclear membrane (INM; Figure 5 ). Furthermore, a1-ARs colocalize with Gaq, a phospholipase C isozyme (PLCb1?), as well as PKCa, d, and e ( Figure 6 ) only at the nucleus. Catecholamines, such as norepinephrine (NE), are actively transported into cardiac myocytes through organic cation transporter-3 (OCT). NE binding to a1-ARs leads to activation of PKC in the nucleus ( Figure 6 ), and nuclear localization is required for signaling ( Figure 2 ). Signals are transported out of the nucleus through the nuclear pore complex (NPC; inhibited by lepB; Figure 4 ). PKCd induces phosphorylation of cTnI at the sarcomere to regulate contractility in adult cardiac myocytes (Figures 1 and 7 ). In addition, nuclear a1-AR signaling induces activation of ERK in caveolae at the plasma membrane to regulate survival signaling in adult cardiac myocytes. cTnI indicates cardiac troponin I; DAG, diacylglycerol; ER/SR, endoplasmic reticulum/sarcoplasmic reticulum; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase kinase; NR, nucleoplasmic reticulum; PKC, protein kinase C; PTP, permeability transition pore; RYR, ryanodine receptor; a1-ARs, a1-adrenergic receptors.
mechanisms whereby intranuclear a1 signaling regulates contractile function are unclear. We cannot exclude the possibility of other contractile regulators that can be mediated by nuclear a1-ARs. For example, although we previously detect PLCb1 at the nucleus, 15 recent studies indicate that the substrate for PLCb1, phosphatidylinositol 4,5-bisphosphate, is not in the nuclear membrane. 38 Therefore, whether
PLCb1 is using a different substrate, or whether a1-ARs signal through a different PLC isoform at the nucleus, remains to be determined.
As recently reviewed, 1,2 a1-ARs are cardioprotective and activating a1-ARs might be a viable therapy in heart failure. This idea is contrary to previous assumptions that all Gqcoupled receptors mediate pathologic remodeling in the heart. 11, 12 However, an important distinction between a1-ARs and other Gq-coupled receptors that do induce pathologic remodeling, such as ET-Rs and AT-Rs, is that a1-ARs localize to the nucleus, whereas the majority of ET-Rs and, possibly, the majority of AT-Rs are expressed at the plasma membrane. [13] [14] [15] This dichotomy in receptor localization (plasma membrane versus nucleus) and outcome (pathologic versus physiologic remodeling) suggests that distinct signaling pathways are activated at the nucleus. This holds true when comparing a1-ARs to b1-ARs as well. It could be argued that nuclear a1-ARs, which mediate more chronic, protective effects, 1,2 act in opposition to plasma membrane b1-ARs, which acutely mediate contractile function, but are maladaptive with chronic stimulation in heart failure. 39 In summary, the nuclear a1-signaling pathway identified here emphasizes physiological distinctions between plasma membrane receptors, such as b1-ARs, ET-Rs, and AT-Rs, versus a1-ARs that might be defined by differential receptor localization. In the basal state, a1-AR-mediated contractility is minor, compared to b-AR-mediated contractility, which provides the majority of inotropic response to catecholamine stimulation. 32 However, evidence suggests that, in the failing heart, a1-AR-mediated contractility becomes proportionally more important. In human papillary muscle strips isolated from failing hearts, a1-AR-mediated inotropic responses were found to be proportionally greater, because b-ARs were desensitized and down-regulated, resulting in reduced b-AR inotropic responses. 40 This is supported by studies in both a1ABKO mice, where pathologic stress reduced contractile function, 6 and a1A transgenic mice, where cardiac-specific overexpression of the a1A subtype increased basal contractile function and protected the heart from pathological stress. 9, 10, 26 However, our current data indicate that, in cultured, unloaded cardiac myocytes, a1-ARs induced a netnegative triphasic inotropic effect where the third phase fails to become positive (Figures 1 through 3 ), which agrees with other studies in isolated mouse cardiac myocytes and right ventricle trabeculae. 22, 23 In contrast, a1-ARs mediated positive triphasic response in Langendorff whole mouse heart preparation 41 and in rat and rabbit myocardial tissue. 23, 42, 43 Therefore, we suspect that the negative inotropic response in the isolated mouse myocyte system simply reflects a unique aspect of this preparation. cTnI is a key regulator of cardiac myocyte contractility. Its phosphorylation by b-adrenergic activation of PKA at serines 23,24, which increases both the rate of relaxation and inotropy, 44 is decreased in failing human hearts. 45 In addition, activation of PKC has been shown to phosphorylate cTnI at serines 43,45 in addition to threonine 144 to decrease calcium sensitivity and contractility. 46 More recently, it was suggested that the way PKCd is activated could also affect the function of cTnI through differential phosphorylation effects. 47 The aim of this study was to identify a novel nucleus to the myofilament pathway affecting cardiac myocyte contractility. Therefore, we focused on the phosphorylation of cTnI at Thr144, a known PKC site that decreases myofilament calcium sensitivity. 48 Increased PKC activity has been reported in cardiac hypertrophy and heart failure. [49] [50] [51] [52] However, the development of therapies targeting abnormal PKC activity in heart failure have met with limited success, perhaps as a result of isoformspecific activities. For example, the conventional (activated by calcium and lipid) PKC isoforms, a and b, have been shown to increase in heart failure. 49, 50 Recently, in a pig model of myocardial infarction, the inhibition of PKCa and b by ruboxistaurin was shown to improve cardiac function after injury. 53 In contrast, for the novel PKC isoforms, d and e, which require only lipid for activation, the inhibition of PKCd 51, 52 or the enhancement of PKCe 51 activities have been shown to ameliorate pathologic hypertrophy. Here, we show that there is a significant amount of PKCd in the nucleus of cardiac myocytes that can be activated by a1-ARs ( Figure 6 ). Because we have shown that a1-ARs are protective against pathological stress, 6,8 it is conceivable that increased PKCd activity by a1-ARs could instead be protective in addition to mediating a1-AR myocyte contractility. In summary, we have uncovered a potentially significant physiological function for nuclear a1-AR (GPCR) signaling in adult cardiac myocytes. Specifically, we identified a novel a1A subtype/PKCd/cTnI inside-out signaling pathway that regulates contractility in adult cardiac myocytes. This work has a broader implication in understanding a1-AR-mediated cardioprotection by identifying a novel nuclear signaling mechanism whereby a1-ARs might protect the heart from pathological stress.
